Bank of New York Mellon
NVCT icon

Bank of New York Mellon’s Nuvectis Pharma NVCT Stock Holding History

Bank of New York Mellon’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$676K Buy
36,770
+6,455
+21% +$72.3K ﹤0.01% 3590
2026
Q1 		$234K Sell
30,315
-1,320
-4% -$11.3K ﹤0.01% 3945
2025
Q4 		$239K Buy
31,635
+3,564
+13% +$23.2K ﹤0.01% 3945
2025
Q3 		$169K Buy
28,071
+832
+3% +$5.72K ﹤0.01% 4052
2025
Q2 		$203K Buy
+27,239
New +$247K ﹤0.01% 3983
2024
Q2 		– Sell
-17,755
Closed -$146K – 4223
2024
Q1 		$146K Sell
17,755
-1,395
-7% -$11.9K ﹤0.01% 3990
2023
Q4 		$160K Hold
19,150
– – ﹤0.01% 4009
2023
Q3 		$247K Hold
19,150
– – ﹤0.01% 3886
2023
Q2 		$306K Buy
+19,150
New +$306K ﹤0.01% 3822

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Bank of New York Mellon's NVCT Position: Q2 2026 in Review

Bank of New York Mellon increased its Nuvectis Pharma (NVCT) stake by 21% in Q2 2026, buying an estimated $72.3K and bringing the position to 36,770 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

Bank of New York Mellon first reported a position in NVCT in Q2 2023 and has held it in 9 quarters since. 35 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Bank of New York Mellon held 36,770 shares of Nuvectis Pharma worth $676K as of Q2 2026.
  • Bank of New York Mellon bought 6,455 Nuvectis Pharma shares in Q2 2026, an estimated $72.3K.
  • Nuvectis Pharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3590 holding.
  • Bank of New York Mellon first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 9 quarters since.
  • 35 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.